Characterization of Vitamin B12 Supplementation and Correlation with Clinical Outcomes in a Large Longitudinal Study of Early Parkinson’s Disease
Objective In Parkinson’s disease (PD), vitamin B12 levels are lower, and comorbid B12 deficiency has been associated with the development of neuropathy and early gait instability. Because little is known about B12 supplement use in PD, we sought to evaluate its use in a large PD cohort and, as an ex...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Movement Disorder Society
2019-05-01
|
| Series: | Journal of Movement Disorders |
| Subjects: | |
| Online Access: | http://www.e-jmd.org/upload/jmd-18049.pdf |
| _version_ | 1797758985682550784 |
|---|---|
| author | Cameron Dietiker Soeun Kim Yunxi Zhang Chadwick W. Christine |
| author_facet | Cameron Dietiker Soeun Kim Yunxi Zhang Chadwick W. Christine |
| author_sort | Cameron Dietiker |
| collection | DOAJ |
| description | Objective In Parkinson’s disease (PD), vitamin B12 levels are lower, and comorbid B12 deficiency has been associated with the development of neuropathy and early gait instability. Because little is known about B12 supplement use in PD, we sought to evaluate its use in a large PD cohort and, as an exploratory analysis, to determine whether baseline characteristics or disease progression differed according to B12 supplementation. Methods We utilized data collected as part of the National Institutes of Health Exploratory Trials in PD (NET-PD) Long-term Study (LS-1), a longitudinal study of 1,741 participants. We stratified subjects into 4 groups according to daily supplement use: no B12, multivitamin (MVI) containing < 100 μg B12, B12 ≥ 100 μg, and MVI + B12 ≥ 100 μg. Clinical outcomes were assessed at 3 years for each group using the Unified Parkinson’s Disease Rating Scale (UPDRS), its subscores, and selected individual questions. Results Of the 1,147 participants who completed the 3-year visit, 41% took an MVI, 2% took B12, 3% took MVI + B12, and 54% reported taking no supplements. At 3 years, no significant differences in clinical outcomes were observed. However, there was a trend toward lower hazard ratios for developing sensory symptoms (UPDRS Item 17) in the MVI (p = 0.08) and B12 + MVI (p = 0.08) groups compared to that in the no supplement group. Conclusion These results show that supplementation with vitamin B12 ≥ 100 μg is uncommon in early PD. The finding of a trend toward a lower hazard ratio for the development of sensory symptoms in those taking an MVI or B12 + MVI warrants further study. |
| first_indexed | 2024-03-12T18:37:53Z |
| format | Article |
| id | doaj.art-731332d2ca054e1a950489c0a23af10d |
| institution | Directory Open Access Journal |
| issn | 2005-940X 2093-4939 |
| language | English |
| last_indexed | 2024-03-12T18:37:53Z |
| publishDate | 2019-05-01 |
| publisher | Korean Movement Disorder Society |
| record_format | Article |
| series | Journal of Movement Disorders |
| spelling | doaj.art-731332d2ca054e1a950489c0a23af10d2023-08-02T07:55:38ZengKorean Movement Disorder SocietyJournal of Movement Disorders2005-940X2093-49392019-05-01122919610.14802/jmd.18049249Characterization of Vitamin B12 Supplementation and Correlation with Clinical Outcomes in a Large Longitudinal Study of Early Parkinson’s DiseaseCameron Dietiker0Soeun Kim1Yunxi Zhang2Chadwick W. Christine3 Department of Neurology, Movement Disorder and Neuromodulation Center, University of California San Francisco, San Francisco, CA, USA Department of Biostatistics and Data Science, University of Texas Health Sciences Center at Houston, Houston, TX, USA Department of Biostatistics and Data Science, University of Texas Health Sciences Center at Houston, Houston, TX, USA Department of Neurology, University of California San Francisco, San Francisco, CA, USAObjective In Parkinson’s disease (PD), vitamin B12 levels are lower, and comorbid B12 deficiency has been associated with the development of neuropathy and early gait instability. Because little is known about B12 supplement use in PD, we sought to evaluate its use in a large PD cohort and, as an exploratory analysis, to determine whether baseline characteristics or disease progression differed according to B12 supplementation. Methods We utilized data collected as part of the National Institutes of Health Exploratory Trials in PD (NET-PD) Long-term Study (LS-1), a longitudinal study of 1,741 participants. We stratified subjects into 4 groups according to daily supplement use: no B12, multivitamin (MVI) containing < 100 μg B12, B12 ≥ 100 μg, and MVI + B12 ≥ 100 μg. Clinical outcomes were assessed at 3 years for each group using the Unified Parkinson’s Disease Rating Scale (UPDRS), its subscores, and selected individual questions. Results Of the 1,147 participants who completed the 3-year visit, 41% took an MVI, 2% took B12, 3% took MVI + B12, and 54% reported taking no supplements. At 3 years, no significant differences in clinical outcomes were observed. However, there was a trend toward lower hazard ratios for developing sensory symptoms (UPDRS Item 17) in the MVI (p = 0.08) and B12 + MVI (p = 0.08) groups compared to that in the no supplement group. Conclusion These results show that supplementation with vitamin B12 ≥ 100 μg is uncommon in early PD. The finding of a trend toward a lower hazard ratio for the development of sensory symptoms in those taking an MVI or B12 + MVI warrants further study.http://www.e-jmd.org/upload/jmd-18049.pdfCyanocobalaminneuropathyneuroprotectiondisease modification |
| spellingShingle | Cameron Dietiker Soeun Kim Yunxi Zhang Chadwick W. Christine Characterization of Vitamin B12 Supplementation and Correlation with Clinical Outcomes in a Large Longitudinal Study of Early Parkinson’s Disease Journal of Movement Disorders Cyanocobalamin neuropathy neuroprotection disease modification |
| title | Characterization of Vitamin B12 Supplementation and Correlation with Clinical Outcomes in a Large Longitudinal Study of Early Parkinson’s Disease |
| title_full | Characterization of Vitamin B12 Supplementation and Correlation with Clinical Outcomes in a Large Longitudinal Study of Early Parkinson’s Disease |
| title_fullStr | Characterization of Vitamin B12 Supplementation and Correlation with Clinical Outcomes in a Large Longitudinal Study of Early Parkinson’s Disease |
| title_full_unstemmed | Characterization of Vitamin B12 Supplementation and Correlation with Clinical Outcomes in a Large Longitudinal Study of Early Parkinson’s Disease |
| title_short | Characterization of Vitamin B12 Supplementation and Correlation with Clinical Outcomes in a Large Longitudinal Study of Early Parkinson’s Disease |
| title_sort | characterization of vitamin b12 supplementation and correlation with clinical outcomes in a large longitudinal study of early parkinson s disease |
| topic | Cyanocobalamin neuropathy neuroprotection disease modification |
| url | http://www.e-jmd.org/upload/jmd-18049.pdf |
| work_keys_str_mv | AT camerondietiker characterizationofvitaminb12supplementationandcorrelationwithclinicaloutcomesinalargelongitudinalstudyofearlyparkinsonsdisease AT soeunkim characterizationofvitaminb12supplementationandcorrelationwithclinicaloutcomesinalargelongitudinalstudyofearlyparkinsonsdisease AT yunxizhang characterizationofvitaminb12supplementationandcorrelationwithclinicaloutcomesinalargelongitudinalstudyofearlyparkinsonsdisease AT chadwickwchristine characterizationofvitaminb12supplementationandcorrelationwithclinicaloutcomesinalargelongitudinalstudyofearlyparkinsonsdisease |